<?xml version='1.0' encoding='utf-8'?>
<document id="28927064"><sentence text="Bortezomib, carfilzomib and ixazomib do not mediate relevant transporter-based drug-drug interactions."><entity charOffset="0-10" id="DDI-PubMed.28927064.s1.e0" text="Bortezomib" /><entity charOffset="12-23" id="DDI-PubMed.28927064.s1.e1" text="carfilzomib" /><entity charOffset="28-36" id="DDI-PubMed.28927064.s1.e2" text="ixazomib" /><pair ddi="false" e1="DDI-PubMed.28927064.s1.e0" e2="DDI-PubMed.28927064.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28927064.s1.e0" e2="DDI-PubMed.28927064.s1.e1" /><pair ddi="false" e1="DDI-PubMed.28927064.s1.e0" e2="DDI-PubMed.28927064.s1.e2" /><pair ddi="false" e1="DDI-PubMed.28927064.s1.e1" e2="DDI-PubMed.28927064.s1.e1" /><pair ddi="false" e1="DDI-PubMed.28927064.s1.e1" e2="DDI-PubMed.28927064.s1.e2" /></sentence><sentence text="In order to optimize the clinical application of an increasing number of proteasome inhibitors, investigations into the differences between their respective pharmacodynamic and pharmacokinetic profiles, including their ability to act as a perpetrator in drug-drug interactions, are warranted" /><sentence text=" Therefore, in the present in vitro study, it was investigated whether bortezomib, carfilzomib and ixazomib are able to alter the expression, and/or the activity, of specific drug transporters generally relevant for pharmacokinetic drug-drug interactions"><entity charOffset="71-81" id="DDI-PubMed.28927064.s3.e0" text="bortezomib" /><entity charOffset="83-94" id="DDI-PubMed.28927064.s3.e1" text="carfilzomib" /><entity charOffset="99-107" id="DDI-PubMed.28927064.s3.e2" text="ixazomib" /><pair ddi="false" e1="DDI-PubMed.28927064.s3.e0" e2="DDI-PubMed.28927064.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28927064.s3.e0" e2="DDI-PubMed.28927064.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28927064.s3.e0" e2="DDI-PubMed.28927064.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28927064.s3.e1" e2="DDI-PubMed.28927064.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28927064.s3.e1" e2="DDI-PubMed.28927064.s3.e2" /></sentence><sentence text=" Through induction experiments, the current study demonstrated that the aforementioned three proteasome inhibitors do not induce mRNA expression of the transporter genes ATP binding cassette (ABC)B1, C1, C2 and G2 in the LS180 cell line, which was used as a model for systemic induction" /><sentence text=" By contrast, in certain myeloma cell lines, ixazomib provoked minor alterations in individual transporter gene expression" /><sentence text=" None of the proteasome inhibitors tested relevantly inhibited drug transporters within the range of physiological plasma concentrations" /><sentence text=" Taken together, transporter-based drug-drug interactions are unlikely to be a primary concern in the clinical application of the tested compounds" /><sentence text="" /></document>